Tvardi stockholders elect directors, approve compensation, and ratify auditor

Tvardi Therapeutics, Inc.

Imran Alibhai, Cynthia Smith, and Sujal Shah elected as Class II directors with 3.51M, 3.39M, 3.51M votes for; 2.98M broker non-votes.
Non-binding advisory vote on executive compensation approved: 3.48M for, 0.16M against, 0.02M abstain.
Stockholders chose 1-year frequency for future advisory votes on executive compensation (3.45M votes for 1 year).
Ratification of Deloitte & Touche as independent auditor for FY2026 passed: 6.52M for, 0.06M against, 0.05M abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tvardi Therapeutics, Inc. shareholders approved Non-Binding, Advisory Vote on Executive Compensation at the 2026-06-09 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 3,482,265 161,795 16,451 2,975,429

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tvardi Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah were each elected to serve as a Class II director of the Company’s Board of Directors until the 2029 Annual Meeting of Stockholders

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tvardi Therapeutics, Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-09 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

3,513,039 147,472 Cynthia Smith 3,392,877 267,634 Sujal Shah 3,507,652 152,859 Broker Non-Votes: 2,975,429 Proposal 2 – Non-Binding, Advisory Vote on Executive Compensation The stockholders approved,

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tvardi Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

The stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Deloitte & Touche LLP

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-072930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.